Will Favipiravir Make it to North America?

By flu, Drugs, Pharmaceutical

Will Favipiravir Make it to North America?

Appili Therapeutics Secures $1m to Cross the Finish Line

TrialSite has extensively chronicled

the use of Favipiravir worldwide as a treatment for early-onset, mild-to-moderate COVID-19.

FUJIFILM Toyama Chemical Co., Ltd. (FUJIFILM)

is the original maker of the drug and has already entered into a license arrangement with Appili Therapeutics to commercialize the drug in Canada and potentially the United States.

A global partnership involving

Appili Therapeutics,
Dr. Reddy’s Laboratories,
FUJIFILM

submitted a market authorization application to Health Canada at the end of 2020.

However,
that submission wasn’t accepted,
and Appili must complete its Phase 3 PRESECO (PREventing Severe COVID-19) clinical trial as a pathway to regulatory approval.

A small Canadian biotech,
Appili just secured a $1 million investment from FUJIFILM,

another member in the global consortium focused on the worldwide development, commercialization, and distribution of Avigan®/Reeqonus™ (favipiravir) tablets for the potential treatment and prevention of COVID-19.

A race is on to secure approval

for antivirals to supply the great majority of COVID-19 cases: the 90%+ of cases involving mild-to-moderate symptomatic COVID-19.

https://trialsitenews.com/will-favipiravir-make-it-to-north-america-appili-therapeutics-secures-1m-to-cross-the-finish-line/

More from tokioX :

  1. Glenmark Pharmaceuticals Reports More Positive Favipiravir Data Associated with COVID-19 Pandemic
  2. NHS Greater Glasgow and Clyde Investigating Favipiravir as Early Onset Treatment for Mild to Moderate COVID-19 in Scotland
  3. Appili Therapeutics Provides Enrollment Update for Its Phase 3 PRESECO Trial Evaluating the Oral Antiviral Favipiravir as an Early Treatment in COVID-19
  4. COVID-19: Dr. Reddy ’s completes AVIGAN trial in Kuwait: therapeutic effect in early infection
  5. COVID-19: FUJIFILM, Phase 3 Avigan clinical trial in the US: ‘Appili Therapeutics’
  6. Mumbai Hospital-led Phase 3 Clinical Trial Reveals the Efficacy of Favipiravir
  7. Favipiravir Sales Skyrocket in India Targeting Mild COVID-19 Cases